主页 > 医学前沿 >
【文摘发布】5-HT终端释放多巴胺是左旋多巴诱导
Authors: Carta M, Carlsson T, Kirik D, Björklund A.
Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden and CNS Disease Modeling Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Resource:Brain. 2007 Apr 23; [Epub ahead of print]
Abstract:
In patients with Parkinson's disease, the therapeutic efficacy of l-DOPA medication is gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually emerge as a prominent side-effect in response to previously beneficial doses of the drug. Here we show that dyskinesia induced by chronic l-DOPA treatment in rats with 6-hydroxydopamine-induced lesions of the nigrostriatal dopamine pathway is critically dependent on the integrity and function of the serotonergic system. Removal of the serotonin afferents, or dampening of serotonin neuron activity by 5-HT(1A) and 5-HT(1 agonist drugs, resulted in a near-complete block of the l-DOPA-induced dyskinesias, suggesting that dysregulated dopamine release from serotonin terminals is the prime trigger of dyskinesia in the rat Parkinson's disease model. In animals with complete dopamine lesions, the spared serotonin innervation was unable to sustain the therapeutic effect of l-DOPA, suggesting that dopamine released as a 'false transmitter' from serotonin terminals is detrimental rather than beneficial. The potent synergistic effect of low doses of 5-HT(1A) and 5-HT(1 agonists to suppress dyskinesia, without affecting the anti-parkinsonian effect of l-DOPA in presence of spared dopamine terminals, suggests an early use of these drugs to counteract the development of dyskinesia in Parkinson's disease patients.
PMID: 17452372 [PubMed - as supplied by publisher] [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-30 15:14
医学,生命科学网